Sacituzumab Govitecan-hziy
GS-US-592-6173
Phase 3 small_molecule active
Quick answer
Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer is a Phase 3 program (small_molecule) at Gilead Sciences Ireland UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences Ireland UC
- Indication
- Triple Negative Breast Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active